Busulfan FDA Link

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Also Known As:

Busulfex; Myleran; Busulfan Wellcome; Glyzophrol; Myelosan; Mylecytan; Myléran; n-Butane-1,3-di(methylsulfonate); Wellcome, Busulfan; Busulphan; 1,4-Butanediol, dimethanesulfonate

Pharmalogical Action Categories:

Alkylating Agents
Antineoplastic Agents, Alkylating
Immunosuppressive Agents
Myeloablative Agonists

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Acyclic Hydrocarbons
    - Alkanes: 241
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        Busulfan: 2106
- Alcohols: 595
  - Glycols: 38
    - Butylene Glycols: 2
      - Busulfan: 2106
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        Busulfan: 2106

M Choma Selected Research

M Choma Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure